[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"geographic-atrophy-secondary-to-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:geographic-atrophy-secondary-to-age-related-macular-degeneration":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,75,98,120,141,153,185,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053340","a-non-interventional-study-observing-short-term-progression-in-geographic-atrophy-ga-100053340",false,"NCT07144137","A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)","A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","Pre-GAIN","Inclusion:\n\n1. Participants must be aged ≥55 years, at the time of signing the informed consent at the screening visit.\n2. Participants with bilateral GA secondary to AMD as confirmed by the Central Reading Center using FAF and\u002For OCT images with at least 1 eye having a total GA lesion area must be between 1.25 mm2 and 17.5 mm2 inclusive, determined by FAF images taken at the screening visit.\n3. Best-corrected visual acuity (BCVA) in both eyes should be sufficient to ensure navigational vision (defined as 20\u002F400 or better for purposes of this study).\n4. BCVA between 20 and 75 letters and LLVA\\>0 letters using an ETDRS chart.\n5. Mean retinal sensitivity as measured by microperimetry using the study grid must be equal to or greater than 5 dB.\n6. Able and willing to provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, and in the opinion of the investigator, is able to perform all study assessments.\n\nExclusion criteria:\n\n1. Macular atrophy secondary to any condition other than AMD in the study eye.\n2. Any pathology of the macula other than GA secondary to AMD and other changes consistent with early, intermediate or atrophic AMD in the study eye.\n3. Evidence of prior or current Choroidal Neovascularization (CNV), also known as wet-AMD, in either eye.\n4. Atrophic retinal disease of causality other than AMD including monogenetic macular dystrophies (incorporating pattern dystrophy), myopia-related maculopathy and Stargardt disease in the study eye.\n5. A history of vitrectomy in the study eye.\n6. Any prior treatment for AMD or any prior intravitreal treatment for any indication in the study eye, except oral supplements of vitamins and minerals such as the age-related eye disease study (AREDS) formula.\n7. Any intraocular surgery (except cataract surgery within 6 months of enrollment) or thermal laser within 3 months of screening, or any ophthalmic condition that may require surgery during the study.\n8. Any macular laser, macular surgery or retinal surgery at any time point in the study eye.\n9. Any ocular or periocular infection in the 12 weeks prior to screening.\n10. History of uveitis or endophthalmitis in either eye.\n11. Any sign of diabetic retinopathy in either eye, or HbA1c \\>8, in the 12 months prior to enrollment.\n12. High myopia or hyperopia (≥6 diopter) in the study eye.\n13. Uncontrolled IOP measurement of ≥25 mmHg for \\>1 month despite being on 2 or more ocular hypotensive agents, or IOP \\>21 mm Hg in the presence of C\u002FD asymmetry of \\>0.3 per the reading center; or glaucomatous damage to the optic nerve or visual field.\n14. Retinal disease other than AMD or other ocular disorders which may cause safety concerns per the judgment of the investigator; however, benign conditions of the vitreous or peripheral retina are not exclusionary (i.e., paving stone degeneration).\n15. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the investigator interferes with ophthalmologic examination (e.g., cataract or corneal abnormalities) either at the time of enrollment or during the 2-year post dosing follow-up period; or prevents adequate imaging of the retina judged by the site or CRC.\n16. Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 60 days prior to baseline.\n17. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the treatment period unlikely, or in general a poor medical risk because of other systemic diseases or active uncontrolled infections, including but not limited to immunodeficiency state, autoimmune diseases, malignancy other than prostate or basal cell carcinoma, connective tissue disorders and collagen vascular disorders.\n18. Participation in an interventional clinical study, or use of any experimental treatment for AMD or any investigational product within 6 months or 5 half-lives of the active ingredient (whichever is longer) prior to screening.\n19. History of abnormal laboratory tests (e.g. hematology, serum chemistry, renal or liver function tests, or infectious disease screen) that in the opinion of the investigator is clinically significant at the time of enrollment and not suitable for study participation.\n20. Hypersensitivity to medications used in (standard of care) study procedures.\n21. Situations where, in the opinion of the investigator, the risk of harm to a participant outweighs any potential benefits from study participation (these could include participants with conditions such as brittle diabetes or advanced osteoporosis as examples).\n22. History or current use of medications associated with macular changes, retinal dysfunction or optic nerve damage. These include but are not limited to the following prohibited concomitant medications:\n23. Any previous gene or cell therapy (ophthalmic or systemic),\n24. Chloroquine (where taken for \\>30 days cumulative across participant's lifetime), hydroxychloroquine, platinum containing medications, ethambutol, tamoxifen, pentosan, chronic use of phosphodiesterase inhibitors, and GLP-1 antagonists in the setting of a crowded optic disc.","ALL","55 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.\n\nThis is a multi-center, non-interventional, observational study which aims to identify participants who have progressive GA to allow quantification of structural and functional parameters that characterize the progression of GA, and to investigate whether these correlate with genetic or lifestyle factors.",[25],"Geographic Atrophy Secondary to Age-related Macular Degeneration",[27,28,29,30,31],"GA","AMD","Geographic atrophy","Dry AMD","Age-related macular degeneration","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-07-30",{"date":40,"type":21},"2027-06-30",{"name":42,"class":43},"Complement Therapeutics","INDUSTRY",13,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100626900","phase-2-a-study-to-investigate-efficacy-and-safety-of-fwy003-compared-with-placebo-in-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100626900","NCT07441642","A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\nMale or female participants ≥ 50 years of age.\n\n* A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.\n\n  1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)\n  2. If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2\n  3. Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy\n* ETDRS BCVA ≥ 35 letters (20\u002F200) in the study eye.\n\nExclusion Criteria:\n\n* A history of, or current evidence of, choroidal neovascularization (exudative MNV) in either eye, as determined by the central reading center on multimodal imaging at screening.\n* Previous cell or gene therapy in either eye.\n* Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.\n* Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.\n* Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or interfere with retinal imaging data quality.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","50 Years",{"count":54,"type":21},272,"INTERVENTIONAL",[57],"PHASE2","To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).",[25],[61,62,63,64],"FWY003","safety","tolerability","geographical atrophy","2026-06-25",{"date":67,"type":36},"2026-06-26",{"date":69,"type":36},"2026-03-09",{"date":71,"type":21},"2029-08-22",{"name":73,"class":43},"Novartis Pharmaceuticals",41,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100609500","phase-2-a-phase-2-randomized-placebo-controlled-multicenter-masked-study-to-evaluate-the-efficacy-safety-tolerability-and-pharmacodynamics-of-multidose-apl-3007-in-combination-with-syfovrepegcetacoplan-apl-2-in-patients-diagnosed-with-geographic-atrophy-secondary-to-age-related-macular-degeneratio-100609500","NCT07215390","A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre\u002FPegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio","A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre\u002FPegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration","Inclusion Criteria:\n\n* The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the study eye.\n* Aged ≥60 years\n* Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes, as determined by the investigator and confirmed by the reading center\n* NL-BCVA of 50 letters or better using early treatment diabetic retinopathy study (ETDRS) charts (approximately 20\u002F100 Snellen equivalent)\n* Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the investigator\n* Prior treatment for GA in the study eye using Syfovre at 6-8 weeks interval for at least 6 months but no more than 24 months. Participants will be included if the participant has had at least 2 Syfovre injections in the last 6 months before screening.\n* The GA lesion in at least 1 eye (designated as the study eye) must meet the following criteria as determined by the central reading center's OCT based RPE assessment of imaging at screening:\n\n  * Total GA area must be ≥2.5 and ≤17.5 mm2 (1-7 disk areas \\[DA\\])\n  * If GA is multifocal, at least 1 focal lesion must be ≥1.25 mm2 (0.5 DA), with the overall aggregate area of GA as specified above in 7a\n  * The entire GA lesion must be completely visualized in the field of view of the OCT, with the GA RPE lesion border \\>500 µm from the edge of the imaging window or any areas of peripapillary atrophy.\n  * Nonsubfoveal lesion with border of GA lesion not encroaching center of the fovea. Distance of GA RPE lesion from center of the fovea \\>0 based on OCT imaging.\n  * Presence of any pattern of hyperautofluorescence based on FAF imaging in the junctional zone of GA. Absence of hyperautofluorescence (ie, pattern = none) is exclusionary.\n* Documented evidence of vaccination within 5 years prior to screening, or willing to initiate vaccinations at least 14 days prior to dosing against:\n\n  * Streptococcus pneumoniae (with a pneumococcal conjugate vaccine 15 \\[PCV15\\] or 20 \\[PCV20\\] or with pneumococcal polysaccharide vaccine 23 \\[PPSV23\\]),\n  * Haemophilus influenzae (type B) (with Hib vaccine),\n  * Neisseria meningitidis types A, C, W, and Y (with a quadrivalent meningococcal conjugate vaccine \\[eg, Menactra or MenQuadfi\\]), and\n  * Neisseria meningitidis type B (with a meningococcal serogroup B vaccine \\[eg, Bexsero\\])\n\nFemale participants must be:\n\n* Women of non-childbearing potential (WONCBP), or\n* Women of childbearing potential (WOCBP) with a negative serum pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study and refrain from breastfeeding for the duration of the study (see Section 10.9.5.1)\n\nMale participants must be surgically sterile or must agree to use highly effective contraception from screening through the duration of the study\n\nWilling and able to provide informed consent and adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n1. Uncontrolled, clinically relevant history of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, or cancer\n2. History or presence of hepatic cirrhosis or other liver disease that may increase the risk of drug-induced liver injury\n3. History or presence of systemic autoimmune disorders, with the exception of well controlled Hashimoto's thyroiditis\n4. History of allergy, hypersensitivity, or serious adverse reaction to siRNA therapy or related compounds, or allergy to any of the components of the study drug\n5. Clinically meaningful abnormalities on diagnostic and laboratory testing must be adjudicated by the sponsor's medical monitor and include:\n\n   1. Cardiac\n\n      Sustained resting heart rate outside of range of 40 to 100 beats\u002Fminute, or a heart rhythm that is not sinus rhythm, confirmed on repeat testing within a maximum of 30 minutes, at screening\n\n      History or evidence of hereditary short QT syndrome\n\n      Fridericia's corrected QT interval (QTcF) \\>480 milliseconds, or the PR interval outside the range of 120 to 220 milliseconds, confirmed on repeat testing within a maximum of 30 minutes at screening\n\n      Any clinically relevant features of acute coronary syndrome (unstable angina, myocardial infarction)\n\n      Any other ECG parameters outside of age-adjusted normative range\n   2. Hepatic\n\n      AST or ALT \\>1.3 × ULN\n\n      Total bilirubin \\>1.1 × ULN\n\n      Any 2 LFTs \\>1.1 × ULN\n\n      Any other LFT parameters outside of age-adjusted normative range\n   3. Renal\n\n   Estimated glomerular filtration rate of less than \\\u003C45 mL\u002Fmin\u002Fm2 as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD- EPI) creatinine equation for adults\n\n   Any other renal function parameters outside of age-adjusted normative range\n6. History or presence of malignancy (except history of basal or squamous cell carcinoma of the skin) that has not been successfully treated ≥1 year prior to enrollment\n7. History or presence of recurrent or unexplained infections, HIV infection, hepatitis B, hepatitis C, or meningococcal infection\n8. Participants with fever (defined as temperature \\>100.4 °F\u002F38 °C) or any acute infection (including COVID-19 infection or infection requiring antibiotic treatment) within 30 days of screening until dosing\n9. Evidence of ongoing drug or alcohol abuse or dependence, in the opinion of the investigator\n10. Intention to donate sperm during this study or within 90 days after the last dose of study drug\n11. Prior administration of APL-3007\n12. Participation in an investigational product or medical device study within 5 half-lives of the investigational product before the screening visit\n13. Has poor peripheral venous access or any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the area intended for SC injection that would interfere with SC injections or assessments of injection local tolerability\n14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator or medical monitor(s), unacceptably increase the participant's risk by participating in the study\n15. Has received a live vaccination (excluding seasonal flu vaccination) within 30 days prior to the first dose administration\n16. Women who are pregnant or breastfeeding\n17. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the treatment period unlikely, or would make the participant an unsafe study candidate\n\n    Ocular specific exclusion criteria apply to the study eye only, unless otherwise specified.\n18. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like plaquenil maculopathy in either eye\n19. Any history of CNV (active or nonexudative\u002Fquiescent) in the study eye associated with AMD or any other cause, including any evidence of RPE rips, double layer sign, or evidence of neovascularization anywhere based on SD-OCT imaging and fluorescein angiography as assessed by the reading center\n20. Presence of an active ocular disease that, in the opinion of the investigator, compromises or confounds visual function, including but not limited to, uveitis, other macular diseases (eg, clinically significant epiretinal membrane, full thickness macular hole or uncontrolled glaucoma\u002Focular hypertension); benign conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary.\n21. History of IVT injection in the study eye within 3 months prior to the screening visit, with the exception of IVT Syfovre\n22. History of any previous investigational product for GA treatment in either eye within 3 months (or 5 half-lives of the investigational drug, whichever is longer) prior to the screening visit\n23. History of laser therapy in the macular region\n24. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the investigator, could compromise visual function during the study period","60 Years",{"count":84,"type":21},240,[57],"A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre\u002FPegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration",[25],"2026-06-23",{"date":90,"type":36},"2026-06-24",{"date":92,"type":36},"2025-06-23",{"date":94,"type":21},"2027-11",{"name":96,"class":43},"Apellis Pharmaceuticals, Inc.",78,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":55,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100623101","phase-1-an-optimised-ga-interventional-trial-opti-gain-to-test-if-treatment-with-ctx001-is-safe-and-works-for-people-with-geographic-atrophy-ga-100623101","NCT07392255","An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)","A First in Human Phase 1 \u002F 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","Opti-GAIN","Inclusion Criteria:\n\nMeet protocol-defined age eligibility\n\nHave bilateral geographic atrophy secondary to AMD, confirmed by the Reading Center\n\nMeet baseline lesion size requirements, as assessed by fundus autofluorescence imaging\n\nMeet best-corrected visual acuity and low-luminance visual acuity criteria, as measured by ETDRS charts\n\nMeet retinal sensitivity criteria, as measured by microperimetry\n\nHave sufficient fellow-eye visual function to ensure navigational vision\n\nHave adequate historical SD-OCT imaging available for longitudinal assessment\n\nMeet reproductive status and contraception requirements, where applicable\n\nBe able and willing to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\nMacular atrophy or retinal disease not attributable to AMD\n\nEvidence of current or prior choroidal neovascularization (wet AMD)\n\nPrior intraocular, macular, or retinal surgery or laser treatment that may confound assessments\n\nPrior AMD-directed or intravitreal therapy in the study eye, except permitted supplements\n\nPrior exposure to complement inhibitor therapies\n\nOcular conditions, infections, inflammation, or media opacities that interfere with safety or retinal imaging\n\nUncontrolled glaucoma, diabetic retinopathy, or clinically significant refractive error\n\nAphakia or compromised posterior capsule, except as permitted by protocol\n\nSystemic medical or psychiatric conditions that may increase risk or limit compliance\n\nRecent participation in another interventional clinical study or exposure to investigational therapies\n\nAny condition that, in the investigator's judgment, poses unacceptable risk or precludes safe participation",{"count":20,"type":21},[108,57],"PHASE1","This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).\n\nSafety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.",[25],"2026-06-18",{"date":113,"type":36},"2026-06-22",{"date":115,"type":36},"2025-12-30",{"date":117,"type":21},"2032-06-30",{"name":42,"class":43},5,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":55,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100592195","phase-2-phase-2-study-of-adx-038-in-participants-with-geographic-atrophy-100592195","NCT06990269","Phase 2 Study of ADX-038 in Participants With Geographic Atrophy","A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","Inclusion Criteria:\n\n* Clinical diagnosis of GA of the macula secondary to AMD\n* GA lesions between 2.5 and 12.5 mm2 at screening\n* Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol\n* Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol\n\nExclusion Criteria:\n\n* Has GA secondary to causes other than AMD\n* Has active ocular disease that compromises or confounds visual function\n* History of surgery for retinal detachment\n* Has ocular condition other than GA secondary to AMD\n* Use of intravitreal complement inhibitors in study eye\n* Hereditary or acquired complement deficiency\n* Active viral, bacterial or fungal infection\n* Liver injury as evidenced by abnormal liver function tests\n* Donating blood\n* History of choroidal neovascularization in the study eye",{"count":84,"type":21},[57],"Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.",[25],"2026-06-12",{"date":133,"type":36},"2026-06-16",{"date":135,"type":36},"2025-11-10",{"date":137,"type":21},"2030-08-30",{"name":139,"class":43},"ADARx Pharmaceuticals, Inc.",27,{"id":142,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":144,"keywords":145,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":151,"locationsCount":152},"100604024",{"count":20,"type":21},[25],[27,28,29,30,31],"2026-06-05",{"date":148,"type":36},"2026-06-08",{"date":38,"type":36},{"date":40,"type":21},{"name":42,"class":43},12,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":55,"phases":163,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":119},"100633841","safety-and-clinical-applicability-of-transcorneal-electrical-stimulation-tes-in-geographic-atrophy-100633841","NCT07531927","Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy","Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy Under Everyday Conditions - a Multicentric, Randomized, Double-masked, Sham-controlled Pilot Study","TES-GAP","Inclusion criteria:\n\n* Willing and able to understand the study and provide informed consent\n* 60 years of age or older\n* Diagnosis of geographic atrophy due to age-related macular degeneration confirmed by imaging\n* The affected area in the eye must be within a defined size range and clearly visible on imaging\n* Eye conditions must allow for good-quality images and reliable measurements\n* Must have a minimum level of visual acuity\n* Women of childbearing potential must have a negative pregnancy test, and must agree to use effective contraception during the study (women who are postmenopausal or surgically sterile are not subject to pregnancy-related requirements)\n\nExclusion criteria:\n\n* History or presence of certain eye conditions (e.g. macular edema, abnormal blood vessel growth or related conditions, retinal detachment, blood vessel blockage) in the study eye\n* Previous major eye surgeries (including retinal surgery or vitrectomy)\n* Previous laser treatment or injections in the study eye\n* Any other eye condition that could interfere with vision tests, imaging or study results\n* Planned eye surgery during the study period\n* Recent treatment with investigational drugs for geographic atrophy\n* Presence of active medical implants\n* Serious or uncontrolled systemic diseases, history of epilepsy or poor general health or conditions affecting the ability to follow study procedures\n* Participation in another clinical study recently or at the same time\n* Breastfeeding, relevant allergies (e.g. to silver), or heavy smoking",{"count":162,"type":21},70,[164],"NA","Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA).\n\nResearchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease.\n\nParticipants will be randomly assigned to one of these three groups:\n\n* TES-treatment with a rectangular stimulus\n* TES-treatment with a repetitive ramp stimulus\n* Placebo (sham) treatment\n\nParticipants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.",[25],[168,169,170,171,172,173,174,175,28],"TES","TcES","OkuStim","OkuStim 2","Okuvision","Electrical Stimulation","Transcorneal Electrical Stimulation","Geographic Atrophy","2026-05-06",{"date":178,"type":36},"2026-05-07",{"date":180,"type":36},"2026-05-05",{"date":182,"type":21},"2028-06",{"name":184,"class":43},"Okuvision GmbH",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":55,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100566975","microcurrent-stimulation-therapy-for-intermediate-to-advanced-nonexudative-age-related-macular-degeneration-100566975","NCT06662162","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.","i-SIGHT2","Key Inclusion Criteria:\n\n* Presence of at least one large druse \\>125 microns in diameter due to AMD.\n* BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6\u002F12 to 6\u002F60 \\[20\u002F40 to 20\u002F200\\])\n\nKey Exclusion Criteria:\n\n* Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and\u002For cardiac defibrillator\u002Fpacemaker.\n* Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and\u002For the grounding electrode (base of the hairline on the back of the neck).\n* Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) \\>10% (13.3 mmol\u002FL).\n* Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).\n* Known severe allergy to fluorescein dye.\n* Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).\n* History of seizure disorders, chronic migraines and\u002For cluster headaches.\n* History and\u002For evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.\n* Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).\n* History and\u002For evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.\n* GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.\n* History of intravitreal injections for GA (e.g., Syfovre or Izervay).\n* Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.\n* Glaucoma requiring ≥3 medications and\u002For drops per day, or history of trabeculectomy.\n* History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.\n* History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \\\u003C1 month from Screening.\n* Visually significant cataracts and\u002For visually significant posterior capsular opacification.\n* History of amblyopia.",{"count":194,"type":21},100,[164],"The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.\n\nParticipants will:\n\n* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.\n* Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.",[198,199,200,25],"Age-Related Macular Degeneration","Age-related Macular Degeneration (ARMD)","Intermediate AMD",[28,200,30,175],"2026-05-01",{"date":204,"type":36},"2026-05-04",{"date":206,"type":36},"2025-05-07",{"date":208,"type":21},"2029-12-31",{"name":210,"class":43},"i-Lumen Scientific AUS PTY LTD",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":55,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100574953","phase-1-a-study-to-evaluate-kriya-825-vv-14295-in-adults-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100574953","NCT06765980","A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","A Phase 1\u002F2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)","VISION","Inclusion Criteria:\n\n* Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form.\n* Body mass index (BMI) of 19 to 34 kg\u002Fm2 (inclusive).\n* Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding.\n* The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening.\n* Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.\n* For study eye, Normal Luminance BCVA of 55 letters or worse using the ETDRS charts (20\u002F80 or worse) for Part 1a participants or 24 letters or better (approximately 20\u002F320 Snellen equivalent) for Part 1b and Part 2 participants.\n* Fellow eye Normal Luminance BCVA of 5 letters or better using ETDRS charts (20\u002F800 or better) for Part 1a participants or 24 letters or better (approximately 20\u002F320 Snellen equivalent or better) for Part 1b and Part 2 participants. Fellow eye must have equivalent or better visual acuity than the study eye.\n\nExclusion Criteria:\n\n* Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy secondary to a condition other than AMD; Exudative AMD diagnosis or any history of or active macular neovascularization (in study eye or fellow eye) and\u002For retinal angiomatous proliferation associated with AMD or any other cause; Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function; Active ocular or periocular infection or active uncontrolled intraocular inflammation within 3 months of Screening; History of vitrectomy, retinal detachment, or corneal transplant in the study eye; Active\u002Fhistory of uveitis.\n* Any ocular condition that prevents adequate imaging.\n* Medical, cognitive or psychiatric conditions that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.\n* Hospitalization within 1 year prior to Screening that, in the opinion of the Investigator, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or could increase the risk to the participant by participating in the study or confound the outcome of the study.\n* Any Screening test (e.g., ECG) or laboratory value (e.g., hematology) that in the opinion of the Investigator and\u002For Medical Monitor is clinically significant and renders the participant not suitable for study participation.\n* Participant has a direct contraindication to the steroid regimen (both oral and topical) or has a condition that significantly increases the risk of complication.\n* Active\u002Fhistory of malignancy within the past 5 years from Screening or any previous therapeutic radiation in the region of the study eye(s) at Screening. History of non-melanoma skin cancers (e.g., basal cell, squamous cell carcinomas), cervical intraepithelial neoplasia (CIN), and localized prostate cancer after treatment are not exclusionary.\n* Intraocular surgery (including lens replacement surgery) within 3 months prior to Screening.\n* History of laser therapy in the macular region.\n* History of intravitreal (IVT) therapy, such as IVT steroid injections, within 6 months prior to Screening.\n* COVID-19 vaccine within 90 days of Screening or plan to receive COVID-19 vaccine within 6 months of treatment.\n* Active use of systemic immunomodulatory drugs or systemic corticosteroids in the last 60 days. Topical steroids are not exclusionary.\n* Prior participation in another interventional clinical study for GA within the past 12 months from the last dosing at Screening.","80 Years",{"count":221,"type":21},62,[108,57],"The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).",[25],"2026-04-29",{"date":227,"type":36},"2026-04-30",{"date":229,"type":36},"2025-05-28",{"date":231,"type":21},"2027-12-15",{"name":233,"class":43},"Kriya Therapeutics, Inc.",3]